Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.

The company is developing three small molecule products: lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγ/RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Stock Quote
Fast Facts
  •  Company Founded in 2016
  •  3 Development Programs
  •  Headquartered in New York City
  •  Experts in Selective Oral Drugs in Immunology
Latest News
May 10, 2022

– Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Expected Next Month – – Part C Portion of Phase 1 Trial of IMU-935 in Psoriasis...

May 5, 2022

– First Time Patients Will be Treated with the Company's Orally Available Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium –...

May 3, 2022

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune...

View All

Contact Us

Immunic Therapeutics
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09

Rx Communications
Paula Schwartz
Managing Director
+1 917 322 2216

To receive all investor alerts please subscribe here
* Required Fields